Uncovering the risks of immunosuppressive therapy in patients with uveitis.
Goldstein
Debra A
DA
D000893:Anti-Inflammatory Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000974:Antibodies, Antinuclear / Q000097:blood; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D001168:Arthritis / Q000139:chemically induced; D002986:Clinical Trials as Topic; D004247:DNA / Q000097:blood; D005500:Follow-Up Studies; D006801:Humans; D000069285:Infliximab; D007262:Infusions, Intravenous; D008180:Lupus Erythematosus, Systemic / Q000139:chemically induced; D013927:Thrombosis / Q000139:chemically induced; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D014605:Uveitis / Q000188:drug therapy*
D000893:Anti-Inflammatory Agents; D000974:Antibodies, Antinuclear; D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D004247:DNA; D000069285:Infliximab